IGPD Inhibitor Compounds for Drug-Resistant Tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug therapies for tuberculosis (TB) face challenges in developing resistance and require new treatments for bacterial infections, particularly in the field of tuberculosis (TB) face challenges in targeting the cell wall and protein biosynthesis of Mycobacterium tuberculosis (Mtb) and the field of tuberculosis (TB) have not addressed the development of resistance against these biological processes.
Innovation Solution
The development of antibacterial compounds targeting imidazoleglycerol-phosphate dehydratase (IGPD), an enzyme in the histidine biosynthesis pathway of Mycobacterium tuberculosis, which is absent in mammals, to inhibit bacterial growth and prevent TB infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drugs target cell wall and protein biosynthesis of Mtb, then bacterial growth is inhibited, but drug resistance develops against these biological processes
Solution Approach 1:
The patent extracts the IGPD enzyme from the broader histidine biosynthesis pathway as a specific drug target. By focusing on IGPD, which is unique to microorganisms and absent in mammals, the invention creates a selective pressure that reduces the likelihood of resistance development while maintaining effective bacterial growth inhibition.
Solution Approach 2:
The patent changes the target parameter from general cell wall and protein biosynthesis processes to a specific enzymatic reaction (IGPD-catalyzed conversion of IGP to imidazoleacetol-phosphate). This parameter change allows for more precise inhibition with reduced risk of resistance.
2Reliability
If IGPD is targeted as a drug target, then selective antibacterial activity is achieved without human homologs, but the complexity of identifying and developing inhibitors increases
Solution Approach 1:
The patent identifies IGPD as a universal target across different microbial pathogens (Mtb, Mycobacterium smegmatis, and other mycobacteria), suggesting that inhibitors developed for this target could have broad spectrum activity against multiple pathogens, justifying the investment in inhibitor development.
Solution Approach 2:
The patent uses computational chemistry and molecular docking as intermediary tools to screen and identify potential IGPD inhibitors. This intermediary approach simplifies the complex task of finding selective inhibitors by using in silico methods before moving to experimental validation.
3Productivity
If de novo histidine biosynthesis pathway is disrupted, then bacterial growth is curtailed, but the pathway's essential role in Mtb viability must be maintained
Solution Approach 1:
The patent applies partial action by targeting only the IGPD enzyme within the histidine biosynthesis pathway, rather than attempting to block the entire pathway. This selective inhibition of the rate-limiting step (IGPD reaction) is sufficient to curtail bacterial growth while maintaining the pathway's essential function for viability.
Data Source
AI summary
The present invention discloses an antibacterial compound of Formula 1 or pharmaceutically acceptable salt thereof:wherein X is CH, S, CH—NH2;R1 is C1-C8 alkyl, substituted alkyl, alkyl amine, substituted amine; preferably R1 is methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, methyl amine, ethylamine, propylamine, isopropyl amine, isobutylamine, N-ethylprop-2-yn-1-amine, N-isopropyl propane-1,3-diamine, N1-isopropyl ethane-1,3-diamine, 1-butyl-2-methylguanidine, N1-ethyl-N1-propylethane-1,2-diamine, cyclobutyamine, phosphate, sulphate;R2 is hydrogen, alkyl, substituted alkyl; preferably R2 is methyl, propyl, isopropyl;R3 is hydrogen, alkyl, substituted alkyl; and preferably R3 is methyl, propyl, isopropyl.The Formula 1 or pharmaceutically acceptable salt thereof is an imidazole glycerol phosphate dehydratase (IGPD) inhibitor and treats or prevents or ameliorates tuberculosis.